Global X Management Company’s Acadia Pharmaceuticals ACAD Stock Holding History

Global X Management Company’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$30K	Buy	1,963 +257	+15%	+$4.58K	﹤0.01%	1161
2018 Q1	$38K	Buy	1,706 +424	+33%	+$11.7K	﹤0.01%	1056
2017 Q4	$39K	Buy	1,282 +305	+31%	+$9.75K	﹤0.01%	947
2017 Q3	$37K	Buy	977 +140	+17%	+$4.55K	﹤0.01%	967
2017 Q2	$23K	Buy	837 +579	+224%	+$17.3K	﹤0.01%	1116
2017 Q1	$9K	Buy	258 +4	+2%	+$141	﹤0.01%	1154
2016 Q4	$7K	Buy	254 +10	+4%	+$265	﹤0.01%	1045
2016 Q3	$8K	Hold	244	–	–	﹤0.01%	1031
2016 Q2	$8K	Buy	+244	New	+$8.17K	﹤0.01%	899

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Global X Management Company's ACAD Position: Q2 2018 in Review

Global X Management Company increased its Acadia Pharmaceuticals (ACAD) stake by 15% in Q2 2018, buying an estimated $4.58K and bringing the position to 1,963 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #1161.

Global X Management Company first reported a position in ACAD in Q2 2016 and has held it in 9 quarters since. The position peaked at $39K in Q4 2017. 187 funds tracked by Wall St. Rank hold ACAD as of Q2 2018.

Global X Management Company held 1,963 shares of Acadia Pharmaceuticals worth $30K as of Q2 2018.
Global X Management Company bought 257 Acadia Pharmaceuticals shares in Q2 2018, an estimated $4.58K.
Acadia Pharmaceuticals made up ﹤0.01% of Global X Management Company's portfolio in Q2 2018, its #1161 holding.
Global X Management Company first reported a position in Acadia Pharmaceuticals in Q2 2016 and has held it in 9 quarters since.
Global X Management Company's Acadia Pharmaceuticals position peaked at $39K in Q4 2017.
187 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2018.

Based on Global X Management Company's 13F filing for Q2 2018, filed 16 Aug 2018.